Cannabis Stocks Face Fresh Delay as DEA Rescheduling Stalls

Two separate Motley Fool reports on October 18 describe the same underlying problem: an order to reschedule marijuana is stuck at the Drug Enforcement Administration, stalling a regulatory shift the cannabis industry has anticipated for over a year. One report focuses on Canopy Growth, the Canada-based cannabis company, noting that larger issues at home compound the federal delay. The other covers Green Thumb Industries, arguing its financial strength could help it weather the holdup better than peers. Rescheduling marijuana from a Schedule I to a Schedule III drug would let US cannabis operators deduct normal business expenses under the tax code, a change that could materially improve after-tax cash flow for companies like Green Thumb that operate domestically. The delay removes a catalyst investors had been pricing in. Neither report gives a new timeline for DEA action, leaving the key question open: whether the delay is a procedural bottleneck or signals a longer stall in the rescheduling process.